Home/Pipeline/Project AlphaSyn

Project AlphaSyn

Parkinson's Disease

Pre-clinicalActive

Key Facts

Indication

Parkinson's Disease

Phase

Pre-clinical

Status

Active

Company

ResQ Biotech

About ResQ Biotech

Founded in 2017 and based in Helsinki, Finland, with significant R&D operations in Patras, Greece, ResQ Biotech is a private, pre-clinical stage company targeting protein misfolding diseases. Its core technology enables high-throughput screening of combinatorial peptide and natural product libraries to identify inhibitors of pathological protein aggregation. Led by a scientifically strong team, including an ERC grantee, the company is advancing its lead program, Project AlphaSyn, against Parkinson's disease while exploring other neurodegenerative indications.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Parkinson's Disease Alzheimer's Disease Amyotrophic Lateral Sclerosis

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active